Page last updated: 2024-12-06
ig 10
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
IG 10: RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 68890 |
| CHEMBL ID | 2106814 |
| SCHEMBL ID | 11406912 |
| SCHEMBL ID | 2111026 |
| SCHEMBL ID | 2111028 |
| MeSH ID | M0132181 |
Synonyms (25)
| Synonym |
|---|
| 72788-52-4 |
| ig-10 |
| loxanast [inn] |
| cis-4-isohexyl-1-methylcyclohexanecarboxylic acid |
| cis-1-methyl-4-(4-methylpentyl)cyclohexanecarboxylic acid |
| loxanast |
| loxanastum [inn-latin] |
| cyclohexanecarboxylic acid, 1-methyl-4-(4-methylpentyl)-, cis- |
| 1-methyl-4-(4-methylpentyl)cyclohexane-1-carboxylic acid |
| cyclohexanecarboxylic acid, 1-methyl-4-(4-methylpentyl)- |
| ig 10 |
| 1-methyl-4-isohexylcyclohexanecarboxylic acid |
| 1-methyl-4-(4-methylpentyl)cyclohexanecarboxylic acid |
| 69915-62-4 |
| 746ywk1b07 , |
| loxanastum |
| unii-746ywk1b07 |
| CHEMBL2106814 |
| loxanast [jan] |
| DTXSID00223116 |
| SCHEMBL11406912 |
| SCHEMBL2111026 |
| SCHEMBL2111028 |
| Q27266258 |
| DTXSID801024455 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 50.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (50.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||